

DAFTAR PUSTAKA

- Aceves, C., Mendieta, I., Anguiano, B., & Delgado-Gonzalez, E. (2021). Molecular iodine has extrathyroidal effects as an antioxidant, differentiator, and immunomodulator. *International Journal of Molecular Sciences*, 22(3), 1–15. <https://doi.org/10.3390/ijms22031228>.
- Aceves, C., Anguiano, B., & Delgado, G. (2013). The extrathyronine actions of iodine as antioxidant, apoptotic, and differentiation factor in various tissues. *Thyroid*, 23(8), 938–948. <https://doi.org/10.1089/thy.2012.0579>.
- Al-jubeh, W., Shaheen, A., & Zalloum, O. (2012). Radioiodine I-131 for diagnosing and treatment of thyroid diseases. *In Students Innovation Conference*. ResearchGate.
- Akhadi, M. (2000). *Dasar-dasar proteksi radiasi*. Jakarta: Rineka Cipta.
- Aliviameita, A., & Puspitasari. (2019). *Buku ajar hematologi* (Edisi pertama). Sidoarjo: UMSIDA Press.
- Anjos, D. A., Etchebehere, E. C., Santos, A. O., Lee, H. C., Lima, M. C., & Camargo, E. E. (2017). Effect of radioiodine therapy on peripheral blood counts in thyroid cancer patients. *Clinical Nuclear Medicine*, 42(5), e219–e224. <https://doi.org/10.1097/RLU.0000000000001585>
- Bahl, P., et al. (2011). Hematologic toxicities following radioactive iodine therapy for thyroid cancer. *Thyroid*, 21(7), 775–780. <https://doi.org/10.1089/thy.2011.0100>.

- Bailey, D. L., Townsend, D. W., Valk, P. E., & Maisey, M. N. (2014). *Positron emission tomography: Basic sciences* (2nd ed.). London: Springer.
- Bikas, A., Van Nostrand, D., Atkins, F., Wartofsky, L., & Burman, K. D. (2016). Hematologic effects of dosimetrically guided radioactive iodine therapy for differentiated thyroid cancer. *Thyroid*, 26(3), 409–416. <https://doi.org/10.1089/thy.2015.0360>
- Bisi, G., et al. (2016). I-131 Therapy in Differentiated Thyroid Cancer. *European Journal of Nuclear Medicine and Molecular Imaging*.
- Bolus, N. E. (2017). Basic review of radiation biology and terminology. *Journal of Nuclear Medicine Technology*, 45(4), 259–264.
- Bombardieri, E., Seregini, E., Evangelista, L., Chiesa, C., & Chiti, A. (2018). *Clinical applications of nuclear medicine targeted therapy*. Cham: Springer. <https://doi.org/10.1007/s00259-018-4202-1>.
- Braverman, L. E., & Cooper, D. S. (2018). *Werner & Ingbar's the thyroid: A fundamental and clinical text* (11th ed.). Wolters Kluwer.
- Brent, G. A. (2012). Mechanisms of thyroid hormone action. *The Journal of Clinical Investigation*, 122(9), 3035–3043. <https://doi.org/10.1172/JCI60047>.
- Bushong, S. C. (2001). *Radiologic science for technologists* (7th ed.). Toronto: Mosby Company.
- Cember, H. (2009). *Introduction to health physics* (4th ed.). New York, NY: The McGraw-Hill Companies, Inc.

- Chen, G. G., Vlantis, A. C., Zeng, Q., & van Hasselt, C. A. (2008). Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. *Cancer Letters*, 270(2), 230–236. <https://doi.org/10.1016/j.canlet.2008.05.024>
- Chowdhury, F. U., & Scarsbrook, A. F. (2016). The role of radioiodine therapy in the management of differentiated thyroid cancer. *Clinical Radiology*, 71(5), 456–470. <https://doi.org/10.1016/j.crad.2016.01.008>.
- Chung, H. R. (2014). Iodine and thyroid function. *Annals of Pediatric Endocrinology & Metabolism*, 19(1), 8–12. <https://doi.org/10.6065/apem.2014.19.1.8>.
- Clarke, S. E. M. (2010). Radioiodine therapy in differentiated thyroid cancer: A nuclear medicine perspective. *In Clinical Oncology* (pp. 1049–1062). Edinburgh: Churchill Livingstone. <https://doi.org/10.1016/j.clon.2010.05.003>.
- Cramer, J. D., Fu, P., Harth, K. C., Margevicius, S., & Wilhelm, S. M. (2010). Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry. *Surgery*, 148(6), 1147–1152. <https://doi.org/10.1016/j.surg.2010.10.016>.
- Daguenet, E., Louati, S., Wozny, A. S., Vial, N., Gras, M., Guy, J. B., et al. (2020). Radiation induced bystander and abscopal effects: Important lessons from preclinical models. *British Journal of Cancer*, 123(3), 339–348. <https://doi.org/10.1038/s41416-020-0922-7>.

- Dainiak, N., Waselenko, J. K., Armitage, J. O., MacVittie, T. J., & Fares, A. M. (2003). The hematologist and radiation casualties. *ASH Education Program Book*, 2003(1), 473–496. <https://doi.org/10.1182/asheducation-2003.1.473>.
- Dai, G., Levy, O., & Carrasco, N. (1996). Cloning and characterization of the thyroid iodide transporter. *Nature*, 379(6564), 458–460. <https://doi.org/10.1038/379458a0>.
- Dahlan, M. S. (2014). *Statistik untuk Kedokteran dan Kesehatan*. Jakarta: Epidemiologi Indonesia.
- Demir, A. N., Kara, Z., Sulu, C., Uysal, S., Zulfaliyeva, G., Atar, O. A., et al. (2023). The effect of radioiodine therapy on blood cell count in patients with differentiated thyroid cancer. *Hormones*, 22, 595–602. <https://doi.org/10.1007/s42000-023-00479-x>.
- Derwahl, M., & Nicula, D. (2014). Estrogen and its role in thyroid cancer. *Endocrine-Related Cancer*, 21(5), T273–T283. <https://doi.org/10.1530/ERC-14-0053>.
- Eberlein, U., Scherthan, H., Bluemel, C., Peper, M., Lapa, C., Buck, A. K., et al. (2016). DNA damage in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy. *Journal of Nuclear Medicine*, 57(2), 173–179. <https://doi.org/10.2967/jnumed.115.164814>.
- Elliyanti, A. (2022). Radiopharmaceuticals in modern cancer therapy. *In Current research for better diagnosis and therapy*. London, UK: IntechOpen. <https://doi.org/10.5772/intechopen.99334>.

- Elliyanti, A. (2022). Molecular radiobiology and radionuclides therapy concepts. *In The evolution of radionanotargeting towards clinical precision oncology: A Festschrift in honor of Kalevi Kairemo* (pp. 395–408). Espoo, Finland: Bentham Books. <https://doi.org/10.2174/9781681088655122010036>.
- Elliyanti, A., Rustam, R., Tofrizal, T., Yenita, Y., & Susanto, Y. D. B. (2021). Evaluating the sodium iodide symporter expressions in thyroid tumors. *Open Access Macedonian Journal of Medical Sciences*, 9(B), 18–23. <https://doi.org/10.3889/oamjms.2021.5534>.
- Environmental Protection Agency (EPA). (2023). Radiation protection: Iodine-131. *U.S. Environmental Protection Agency*. <https://www.epa.gov/radiation/radionuclide-basics-iodine-131>.
- Evron, J. M., Esfandiari, N. H., & Papaleontiou, M. (2020). Cancer incidence and mortality following treatment of hyperthyroidism with radioactive iodine. *Current Opinion in Endocrinology, Diabetes and Obesity*, 27(5), 323–328. <https://doi.org/10.1097/MED.0000000000000561>.
- Fard-Esfahani, A., Emami-Ardekani, A., Fallahi, B., Fard-Esfahani, P., Beiki, D., Hassanzadeh-Rad, A., et al. (2014). Adverse effects of radioactive iodine-131 treatment for differentiated thyroid carcinoma. *Nuclear Medicine Communications*, 35(8), 808–817. <https://doi.org/10.1097/MNM.0000000000000132>.
- Fatourechi, V., Hay, I. D., Mullan, B. P., & Wiseman, G. A. (2016). Are there hematological side effects of low-dose radioiodine therapy in patients with thyroid cancer, *Thyroid*, 26(7), 913–918. <https://doi.org/10.1089/thy.2016.0501>

- Ghaly, M., Links, J. M., & Frey, E. C. (2019). Quantitative SPECT/CT imaging in radiation dosimetry and targeted radionuclide therapy. *Radiographics*, 39(2), 346–360. <https://doi.org/10.1148/rg.2019180108>.
- Gulde, S., et al. (2015). Bone marrow function after ¹³¹I therapy in patients with differentiated thyroid carcinoma. *The Journal of Clinical Endocrinology & Metabolism*, 100(10), 3911–3918. <https://pubmed.ncbi.nlm.nih.gov/26262436/>
- Guyton, A. C., & Hall, J. E. (2021). *Textbook of medical physiology (14th ed.)*. Elsevier.
- Hall, E. J., & Giaccia, A. J. (2018). *Radiobiology for the radiologist (8th ed.)*. Philadelphia, PA: Wolters Kluwer.
- Hall, E. J., & Giaccia, A. J. (2012). *Radiobiology for the radiologist (7th ed.)*. Philadelphia, PA: Lippincott Williams & Wilkins.
- Haugen, B. R., Alexander, E. K., Bible, K. C., et al. (2016). 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. *Thyroid*, 26(1), 1–133. <https://doi.org/10.1089/thy.2015.0020>.
- Heesch, A., Maurer, J., Stickeler, E., Beheshti, M., Mottaghy, F. M., & Morgenroth, A. (2020). Development of radiotracers for breast cancer: The tumor microenvironment as an emerging target. *Cells*, 9(10), 2334. <https://doi.org/10.3390/cells9102334>.
- Hiswara, E. (2015). *Buku pintar proteksi dan keselamatan radiasi di rumah sakit*. Jakarta: BATAN Press.

- Hoffbrand, A. V., Higgs, D. R., Keeling, D. M., & Mehta, A. B. (2019). *Postgraduate haematology (7th ed.)*. Hoboken, NJ: Wiley-Blackwell. <https://doi.org/10.1002/9781119495901>.
- Hoffbrand, A. V., & Moss, P. A. H. (2016). *Essential haematology (7th ed.)*. Hoboken, NJ: Wiley-Blackwell.
- Hoffman, J. R., & Tschöp, M. H. (2018). Iodine, thyroid function, and immunity. *Journal of Clinical Endocrinology & Metabolism*, *103*(3), 103–110. <https://doi.org/10.1210/jc.2017-01832>.
- Huang, Y., Dong, W., Li, J., Zhang, H., Shan, Z., Teng, W., & Yu, X. (2014). Differential expression patterns and clinical significance of estrogen receptor- α and estrogen receptor- β in papillary thyroid carcinoma. *BMC Cancer*, *14*, 383. <https://doi.org/10.1186/1471-2407-14-383>
- Ilusanya, O., Adedapo, A., & Salawu, O. (2020). Hematological effects of radioactive iodine therapy in patients with thyroid disorders. *Journal of Radiation Research*, *61*(4), 592–599. <https://doi.org/10.1093/jrr/rraa037>
- International Atomic Energy Agency. (2018). *Radiation protection and safety of radiation sources: International basic safety standards (IAEA Safety Standards Series No. GSR Part 3)*. Vienna: International Atomic Energy Agency.
- International Atomic Energy Agency (IAEA). (2011). *Radiation Biology: A Handbook for Teachers and Students*. Vienna.
- International Commission on Radiological Protection. (2012). ICRP statement on tissue reactions/early and late effects of radiation in normal tissue and organs (ICRP Publication 118). *Annals of the ICRP*, *41*(1–2), 1–322. <https://doi.org/10.1016/j.icrp.2012.02.001>.

International Commission on Radiological Protection. (2007). The 2007 recommendations of the International Commission on Radiological Protection (ICRP Publication 103). *Annals of the ICRP*, 37(2-4), 1-332. <https://doi.org/10.1016/j.icrp.2007.10.003>.

Jadiyappa, S. (2018). Radioisotope: Applications, effects, and occupational protection. In R. O. Abdel Rahman & H. E.-D. M. Saleh (Eds.), *Principles and applications in nuclear engineering: Radiation effects, thermal hydraulics, radionuclide migration in the environment* (pp. 19-47). IntechOpen. <https://doi.org/10.5772/65990>.

Jameson, J. L., & Fauci, A. S. (2018). *Harrison's endocrinology (4th ed.)*. New York: McGraw-Hill Education.

Jentzen, W., Bockisch, A., & Grünwald, F. (2010). Therapeutic I-131 activity calculation in differentiated thyroid cancer using lesion dosimetry and I-124 PET/CT imaging. *European Journal of Nuclear Medicine and Molecular Imaging*, 37(11), 1868-1879. <https://doi.org/10.1007/s00259-010-1516-2>.

Joseph, L. J., Bhartiya, U. S., Raut, Y. S., Kand, P., Hawaldar, R. W., & Nair, N. (2009). Micronuclei frequency in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy and its relationship with metastasis. *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*, 675(1-2), 35-40. <https://doi.org/10.1016/j.mrgentox.2009.02.004>.

Karanikas, G., Schuetz, M., Hermann, M., et al. (2004). Hematological changes following radioiodine therapy for thyroid carcinoma. *Clinical Nuclear Medicine*, 29(12), 843-847. <https://doi.org/10.1097/01.rlu.0000146516.57436.13>.

- Kaushansky, K., Lichtman, M. A., Prchal, J. T., Levi, M. M., Press, O. W., Burns, L. J., & Caligiuri, M. A. (2018). *Williams hematology (9th ed.)*. New York: McGraw-Hill Education.
- Kayal, G., Barbosa, N., Marín, C. C., et al. (2024). Quality assurance considerations in radiopharmaceutical therapy dosimetry: International Atomic Energy Agency study. *Journal of Nuclear Medicine*, *65*(1), 125–131. <https://doi.org/10.2967/jnumed.122.265340>.
- Kemenkes RI. (2017). *Panduan Penatalaksanaan Kanker Tiroid*. Komite Penanggulangan Kanker Nasional.
- Kim, T. H., Kim, Y. N., Kim, H. I., et al. (2013). Hematologic changes after radioactive iodine ablation therapy in patients with differentiated thyroid carcinoma. *Nuclear Medicine Communications*, *34*(11), 1140–1146.
- Klecha, A. J., Barreiro, L., Arcos, M. L., Frick, L., Genaro, A. M., & Cremaschi, G. (2008). Immune-endocrine interactions in autoimmune thyroid diseases. *Neuroimmunomodulation*, *15*(1), 68–75. <https://doi.org/10.1159/000135626>.
- Knoll, G. F. (2010). *Radiation detection and measurement (4th ed.)*. Hoboken: John Wiley & Sons.
- Lassmann, M., & Hänscheid, H. (2011). Dosimetry in radioiodine therapy of benign thyroid diseases. *Journal of Nuclear Medicine*, *52*(1), 57–65. <https://doi.org/10.2967/jnumed.110.079855>.
- Lesmana, R., Widodo, D., & Sari, R. (2019). Perubahan hematologi pada pasien hipertiroid pasca terapi radioiodin dosis rendah. *Jurnal Kedokteran Brawijaya*, *30*(2), 123–129.

Little, J. B. (2000). Radiation carcinogenesis. *Carcinogenesis*, 21(3), 397–404. <https://doi.org/10.1093/carcin/21.3.397>.

Liu, H., Chen, Q., Liu, B., Wang, J., Chen, C., & Sun, S. (2023). Blood profiles in the prediction of radioiodine refractory papillary thyroid cancer: A case–control study. *Journal of Multidisciplinary Healthcare*, 16, 535–546. <https://doi.org/10.2147/JMDH.S403045>.

Liu, J., & Xu, J. (2019). Beta radiation and its applications in radiotherapy. *Medical Physics*, 46(10), 4355–4363. <https://doi.org/10.1002/mp.13814>.

Luster, M., Clarke, S. E., Dietlein, M., Lassmann, M., Lind, P., Oyen, W. J. G., Tennvall, J., & Bombardieri, E. (2008). Guidelines for radioiodine therapy of differentiated thyroid cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, 35(10), 1941–1959. <https://doi.org/10.1007/s00259-008-0883-1>

Maia, G. A. S., De Oliveira, R. C., Medina, J. M., Da Silveira, A. B., Mignaco, J. A., & Atella, G. C., et al. (2014). The effect of gamma radiation on the lipid profile of irradiated red blood cells. *Annals of Hematology*, 93(5), 753–760. <https://doi.org/10.1007/s00277-013-1944-5>.

Mandal, P., Sarkar, B. R., & Ray, A. (2020). Oxidative stress-mediated hematological toxicity induced by ionizing radiation: A brief review. *International Journal of Radiation Biology*, 96(8), 1053–1065. <https://doi.org/10.1080/09553002.2020.1740431>.

Maulidiyanti, E. T. S., Widiyastuti, R., & Saputro, T. A. (2024). *Hematologi dasar*. Malang: Rena Cipta Mandiri.

- Maxon, H. R., Smith, H. S., Coady, G. C., Ritschel, W. A., Samsa, G. P., & Buncher, C. R. (1983). Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. *New England Journal of Medicine*, *309*(14), 937–941. <https://doi.org/10.1056/NEJM198310063091403>.
- McGrogan, A., Seaman, H. E., Wright, J. W. D. E., & Vries, C. S. (2008). The incidence of autoimmune thyroid disease: A systematic review of the literature. *Clinical Endocrinology*, *69*(5), 687–696. <https://doi.org/10.1111/j.1365-2265.2008.03338.x>.
- McKenzie, S. B., Williams, J. L., & Bishop, J. M. (2019). *Clinical laboratory hematology (4th ed.)*. New York: Pearson.
- Mihailovic, J. (2025). Evolving paradigm in radioactive iodine therapy for differentiated thyroid cancer: Historical perspectives, current practices and future directions. *Diagnostics*, *15*(11), 1438. <https://doi.org/10.3390/diagnostics15111438>.
- Monzen, S., Mariya, Y., Wojcik, A., Kawamura, C., Nakamura, A., Chiba, M., et al. (2015). Predictive factors of cytotoxic damage in radioactive iodine treatment of differentiated thyroid cancer patients. *Molecular and Clinical Oncology*, *3*(3), 692–698. <https://doi.org/10.3892/mco.2015.499>.
- Mullur, R., Liu, Y. Y., & Brent, G. A. (2014). Thyroid hormone regulation of metabolism. *Physiological Reviews*, *94*(2), 355–382. <https://doi.org/10.1152/physrev.00030.2013>.
- Mutohar, A., Setiabudi, W., & Shintawati, R. (2017). Laju paparan dan dosis radiasi dari pasien terapi kelainan kelenjar tiroid dengan pemberian radiofarmaka Iodium-131. *Youngster Physics Journal*, *6*(1), 22–31.

- Pacini, F., et al. (2016). Effects of dosimetrically guided I-131 therapy on hematopoiesis in patients with differentiated thyroid cancer. *Journal of Nuclear Medicine*, 57(5), 123–130. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4880173/>
- Pagana, K. D., & Pagana, T. J. (2021). *Mosby's diagnostic and laboratory test reference (15th ed.)*. St. Louis: Elsevier.
- Palestine Polytechnic University. (2022). *Nuclear physics lecture notes*. Hebron: Department of Applied Physics, Faculty of Applied Sciences.
- Panneels, V., Juvenal, G., Boeynaems, J. M., Dumont, J. E., & Van Sande, J. (2009). Iodide effects on the thyroid: Biochemical, physiological, pharmacological, and clinical effects of iodide in the thyroid. In V. R. Preedy, G. N. Burrow, & R. Watson (Eds.), *Comprehensive handbook of iodine: Nutritional, biochemical, pathological and therapeutic aspects* (pp. 303–314). Elsevier. <https://doi.org/10.1016/B978-0-12-374135-6.00032-7>.
- Patel, S. P., & Ghosh, P. (2021). Alpha radiation: A review of biological impact and application in nuclear medicine. *Journal of Nuclear Medicine*, 62(7), 919–925. <https://doi.org/10.2967/jnumed.120.258196>.
- Pedersen, I. B., Knudsen, N., Carle, A., Vejbjerg, P., Jorgensen, T., Perrild, H., Ovesen, L., Rasmussen, L. B., & Laurberg, P. (2011). A cautious iodization programme bringing iodine intake to a low recommended level is associated with an increase in the prevalence of thyroid autoantibodies in the population. *Clinical Endocrinology*, 75(1), 120–126. <https://doi.org/10.1111/j.1365-2265.2011.04008.x>.

- Perlman, J. A., & Sternthal, P. M. (1983). Effect of I-131 on the anemia of hyperthyroidism. *Journal of Chronic Diseases*, 36(6), 405–412. [https://doi.org/10.1016/0021-9681\(83\)90173-X](https://doi.org/10.1016/0021-9681(83)90173-X)
- Piciu, D., et al. (2014). Haematological changes after radioiodine therapy in differentiated thyroid carcinoma patients. *Endocrine Journal*, 61(11), 1069–1074.
- Prinsen, H. T., Klein Hesselink, E. N., Brouwers, A. H., Plukker, J. T. M., Sluiter, W. J., & Links, T. P. (2015). Bone marrow function after radioactive iodine therapy in patients with differentiated thyroid carcinoma. *The Journal of Clinical Endocrinology & Metabolism*, 100(10), 3911–3917. <https://doi.org/10.1210/jc.2015-2074>
- Podgorsak, E. B. (2005). *Radiation physics for medical physicists (7th edition)*. Berlin, Heidelberg. Springer.
- Rodak, B. F., Fritsma, G. A., & Keohane, E. M. (2020). *Hematology: Clinical principles and applications (6th ed.)*. St. Louis: Elsevier.
- Rahbari, R., Zhang, L., & Kebebew, E. (2010). Thyroid cancer gender disparity. *Future Oncology*, 6(11), 1771–1779. <https://doi.org/10.2217/fon.10.127>
- Rasyada, L. A., Fardela, R., & Elliyanti, A. (2025). Optimalisasi terapi radioaktif yodium (RAI) pada kanker tiroid: Tinjauan literatur. *Jurnal Penelitian Sains*, 27(3C), 1–10. <https://doi.org/10.56064/jps.v27i3.1224>
- Rubino, C., de Vathaire, F., Dottorini, M. E., et al. (2005). Second primary malignancies in thyroid cancer patients treated with radioiodine. *British Journal of Cancer*, 92(2), 376–382.
- Rui, Z., Wu, R., Zheng, W., Wang, X., Meng, Z., & Tan, J. (2021). Effect of I-131

therapy on complete blood count in patients with differentiated thyroid cancer. *Medical Science Monitor*, 27, e929590. <https://doi.org/10.12659/MSM.929590>.

Runkle, C. M., Silverman, D. A., & Mehra, S. (2017). Hematologic effects of radioactive iodine therapy for thyroid cancer. *Head & Neck*, 39(1), 111–116. <https://doi.org/10.1002/hed.24550>

Schlumberger, M., Catargi, B., Borget, I., et al. (2009). Strategies of radioiodine ablation in patients with low-risk thyroid cancer. *The New England Journal of Medicine*, 360(9), 923–932. <https://doi.org/10.1056/NEJMoa0810043>

Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020). Radiopharmaceutical therapy in cancer: Clinical advances and challenges. *Nature Reviews Drug Discovery*, 19(9), 589–608. <https://doi.org/10.1038/s41573-020-0073-9>.

Siegel, J. A., Yeldell, D., Goldenberg, D. M., Stabin, M. G., Sparks, R. B., Sharkey, R. M., et al. (2003). Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: Improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. *Journal of Nuclear Medicine*, 44(1), 67–76.

Silberstein, E. B. (2021). Hematologic effects of radioiodine therapy. *Seminars in Nuclear Medicine*, 51(1), 75–81. <https://doi.org/10.1053/j.semnuclmed.2020.09.007>

Silva, J. E. (2018). Thyroid hormone control of thermogenesis and energy balance. *Thyroid*, 28(8), 961–970. <https://doi.org/10.1089/thy.2017.0328>

Sisson, J. C., Freitas, J., McDougall, I. R., et al. (2003). Radiation safety in the treatment of patients with thyroid diseases by radioiodine (I-131): Practice recommendations of the American Thyroid Association. *Thyroid*, *13*(10), 943–951. <https://doi.org/10.1089/105072503322401038>.

Sisson, J. C., Freitas, J., McDougall, I. R., Dauer, L. T., Hurley, J. R., Brierley, J. D., ... Rosenthal, D. S. (2018). Radiation safety in the treatment of patients with thyroid diseases by radioiodine. *Seminars in Nuclear Medicine*, *48*(2), 96–109. <https://doi.org/10.1053/j.semnuclmed.2017.10.003>

Soffiatti, R., Trevisan, E., & Rudà, R. (2018). Neurological complications of systemic cancer therapies. *Nature Reviews Neurology*, *14*(12), 723–739. <https://doi.org/10.1038/s41582-018-0097-8>.

Spitzweg, C., Harrington, K. J., Pinke, L. A., Vile, R. G., & Morris, J. C. (2001). The sodium iodide symporter and its potential role in cancer therapy. *Journal of Clinical Endocrinology & Metabolism*, *86*(7), 3327–3335. <https://doi.org/10.1210/jcem.86.7.7638>.

Stabin, M. G. (2008). Radiopharmaceuticals for nuclear cardiology: Radiation dosimetry, uncertainties, and risk. *Journal of Nuclear Medicine*, *49*(9), 1555–1563. <https://doi.org/10.2967/jnumed.108.052241>.

Sugiyono. (2017). *Statistika untuk Penelitian*. Bandung: Alfabeta.

Syafriani, D., Darmana, A., Syuhada, F. A., & Sari, D. P. (2023). *Buku ajar statistik uji beda untuk penelitian pendidikan: Cara dan pengolahannya dengan SPSS*. Jakarta: Eureka Media Aksara.

Talapko, J., Talapko, D., Katalinic, D., Kotris, I., Eric, I., Belic, D., Mihaljevic,

- M. V., Vasilj, A., Eric, S., Flam, J., Bekic, S., Matic, S., & Skrlec, I. (2024). Health effects of ionizing radiation on the human body. *Medicina*, *60*(4), 653. <https://doi.org/10.3390/medicina60040653>.
- Teng, X., Shan, Z., Chen, Y., Lai, Y., Yu, J., Shan, L., Bai, X., Li, Y., Li, N., Li, Z., Wang, S., Xing, Q., Xue, H., Zhu, L., Hou, X., Fan, C., & Teng, W. (2011). More than adequate iodine intake may increase subclinical hypothyroidism and autoimmune thyroiditis: A cross-sectional study based on two Chinese communities with different iodine intake levels. *European Journal of Endocrinology*, *164*(6), 943–950. <https://doi.org/10.1530/EJE-10-1041>.
- Thom, C. S., Dickson, C. F., Gell, D. A., & Weiss, M. J. (2013). Hemoglobin variants: Biochemical properties and clinical correlates. *Cold Spring Harbor Perspectives in Medicine*, *3*(3), a011858. <https://doi.org/10.1101/cshperspect.a011858>.
- Tuttle, R. M., Leboeuf, R., & Robbins, R. J. (2008). Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer. *Current Opinion in Oncology*, *20*(1), 33–38. <https://doi.org/10.1097/CCO.0b013e3282f2f3aa>.
- United Nations Scientific Committee on the Effects of Atomic Radiation. (2010). *Sources and effects of ionizing radiation: UNSCEAR 2010 report to the General Assembly with scientific annexes* (Vol. 1). United Nations. <https://www.unscear.org/unscear/en/publications/2010>.

United Nations Scientific Committee on the Effects of Atomic Radiation. (2008). *Sources and effects of ionizing radiation: UNSCEAR 2008 report to the General Assembly with scientific annexes* (Vol. 1). United Nations. https://www.unscear.org/docs/publications/2008/UNSCEAR_2008_Report_Vol.I.pdf.

Vitale, M., Di Matola, T., D'Ascoli, F., Salzano, S., Bogazzi, F., Fenzi, G., et al. (2000). Iodide excess induces apoptosis in thyroid cells through a p53-independent mechanism involving oxidative stress. *Endocrinology*, *141*(2), 598–605. <https://doi.org/10.1210/endo.141.2.7291>.

Vigneri, R., Malandrino, P., & Vigneri, P. (2015). The role of sex hormones in the pathogenesis of thyroid cancer. *Journal of Endocrinological Investigation*, *38*(3), 269–276. <https://doi.org/10.1007/s40618-014-0204-3>

Vrndic, O., Milošević-Đorđević, O., Djurdjevic, P., Jovanovic, D., Mijatovic, L., Jeftic, I., et al. (2013). Radioiodine therapy accelerates apoptosis in peripheral blood lymphocytes of patients with differentiated thyroid cancer. *Neoplasma*, *60*(1), 74–80. https://doi.org/10.4149/neo_2013_074.

Watanabe, N., Yokoyama, K., & Kinuya, S. (2018). Hematologic changes after radioactive iodine therapy for thyroid carcinoma. *Annals of Nuclear Medicine*, *32*(3), 210–218. <https://doi.org/10.1007/s12149-018-1263-5>

Ward, W. F. (2006). Basic principles of radiation biology. In R. E. Henkin, D. Bova, G. L. Dillehay, et al. (Eds.), *Nuclear medicine* (pp. 507–522). Philadelphia: Mosby Elsevier.

- Wartofsky, L., & Van Nostrand, D. (2016). Radioiodine in the treatment of thyroid cancer. *Endocrinology and Metabolism Clinics of North America*, 45(3), 735–760. <https://doi.org/10.1016/j.ecl.2016.04.009>.
- Widel, M. (2017). Radionuclides in radiation-induced bystander effect: May it share in radionuclide therapy? *Neoplasma*, 64(5), 641–654. https://doi.org/10.4149/neo_2017_501.
- Yang, L., Ma, J., Lei, P., Yi, J., Ma, Y., Huang, Z., et al. (2023). Advances in antioxidant applications for combating I-131 side effects in thyroid cancer treatment. *Toxics*, 11(6), 529. <https://doi.org/10.3390/toxics11060529>.
- Yeong, C. H., Cheng, M. H., & Ng, K. H. (2014). Therapeutic radionuclides in nuclear medicine: Current and future prospects. *Journal of Zhejiang University-SCIENCE B*, 15(10), 845–863. <https://doi.org/10.1631/jzus.B1400131>.
- Yoon, J. H., Son, Y. I., Lee, H. K., & Kim, K. M. (2014). Hematological changes after high-dose radioiodine therapy in patients with differentiated thyroid carcinoma. *Annals of Nuclear Medicine*, 28(3), 276–281. <https://doi.org/10.1007/s12149-013-0806-9>.
- Yuldasheva, N., Khasanov, S., & Ergashev, A. (2019). The effect of I-131 therapy on hematological parameters in patients with thyroid cancer. *Endocrine Connections*, 8(12), 1527–1534. <https://doi.org/10.1530/EC-19-0478>
- Zanzonico, P. (2011). Radiation dose to patients and relatives incident to 131I therapy. *Thyroid*, 21(5), 471–476. <https://doi.org/10.1089/thy.2010.0411>

Zhang, X., & Liu, T. (2020). Gamma radiation detection: Principles and applications. *Radiation Protection Dosimetry*, 188(1), 1–12. <https://doi.org/10.1093/rpd/ncaa001>.

Ziessman, H. A., O'Malley, J. P., & Thrall, J. H. (2014). *Nuclear medicine: The requisites (4th ed.)*. Elsevier Saunders.

Zimmermann, M. B., & Galetti, V. (2015). Iodine intake as a risk factor for thyroid cancer: A comprehensive review of animal and human studies. *Thyroid Research*, 8(1), 1–15. <https://doi.org/10.1186/s13044-015-0020-8>.

